SiBionics presented an exhibition and an industry symposium at the European Association for the Study of Diabetes (EASD) 2026 meeting in Milan under the theme "See More, Act Earlier," the company said in its announcement. The exhibition was divided into three chapters, covering glucose, ketone and combined monitoring; multimodal sensing and insulin delivery; and broader biosensing applications.
The symposium, "From Sensors to Integrated Care: Emerging Technologies Shaping the Future of Diabetes Management," was chaired by Prof. Mark Evans of the University of Cambridge and Cambridge University Hospitals in the United Kingdom and Dr. Guido Freckmann of the Institute for Diabetes-Technology GmbH (IfDT) in Germany. Prof. Karolina Kędzierska-Kapuza discussed CGM and individualized care in type 3c diabetes, Prof. Wei Qiang presented CGM accuracy findings and future multimodal sensing concepts, and Prof. Andrej Janež explored continuous ketone monitoring in the GLP-1 era. Prof. Ahmad Haidar presented ketone monitoring research together with the first findings of the SMART02 feasibility study on integrated glucose sensing and insulin delivery.
SMART02 evaluated an early prototype of niia signature, an investigational device that PharmaSens and SiBionics have developed jointly since announcing their collaboration in June 2025. The companies said the device is designed to combine CGM, insulin delivery and an automated glucose control (AGC) algorithm in one wearable patch, with the aim of reducing the burden of managing separate devices for automated insulin delivery (AID).
The study addressed a central integration challenge: maintaining glucose measurement performance when insulin is delivered close to the sensor. Temporary interference after a bolus was uncommon overall and occurred mainly with doses of 10 units or more, where the probability was 20 to 25 percent, the companies said, and on average the sensor signal recovered fully about 20 minutes after bolus delivery. In the second part of the study, the prototype was tested with the AGC algorithm developed by Prof. Ahmad Haidar; the PharmaSens niia patch pump, the SiBionics sensor and the algorithm performed consistently throughout. The companies described the findings, also featured at the SiBionics booth, as an early development milestone.
niia signature is an investigational device, the companies said. It is not approved or cleared in any market and is not available for sale, and further research is needed to establish its performance and clinical potential.
